CTNM
Neutral signalScored 2026-08-05 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Contineum Therapeutics, Inc.
- Nom
- Contineum Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $270.3M
- Employés
- 51
- PDG
- Carmine N. Stengone
- Site web
- https://www.contineum-tx.com
- Marché
- ACIUANROGHRSLBRXMPLTNMRA
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 5 000 titres (~81 170,50 $ US)
- Insiders
- Stengone Carmine N.
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$81,170
Avg sell (VWAP, 90d window) $16.23 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$81,170 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-09-08
- Last synced
-
2026-09-14 09:51:34
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-08 | Stengone Carmine N. | Sell · S · 10b5-1 | 2,500 | $16.46 | $41,142 | Form 4 |
| 2026-08-03 | Stengone Carmine N. | Sell · S · 10b5-1 | 2,500 | $16.01 | $40,029 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-08-05 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
CTNM presents a deceptive liquidity profile: the high liquidity ratio (85) reflects an operationally dormant shell rather than genuine financial strength, as the company reports zero revenue, negative margins, and no…
The first sentence of the analysis written for CTNM on 2026-08-05 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $81K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $81K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Supports a bullish reading. Current ratio 27.50 · operating margin 0.0%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 46.8% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 47.1% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | -32.2% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 46.3% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 45.4% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 45.4% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 45.4% | 0.0% | 0.0% | |
| Current Ratio | 27.496 | 20.693 | 23.287 | 6.410 | 18.993 | |
| Quick Ratio | 27.496 | 20.693 | 23.287 | 6.410 | 18.993 | |
| Solvency Ratio | -3.811 | -2.841 | 0.116 | -2.105 | -3.211 | |
| Cash Ratio | 7.759 | 2.200 | 2.831 | 0.738 | 1.260 | |
| Price To Earnings Ratio | -5.267 | -8.988 | 118.462 | -15.876 | -13.391 | |
| Price To Earnings Growth Ratio | -0.159 | 0.007 | -1.045 | 1.014 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -0.159 | 0.007 | -1.045 | 1.014 | 0.000 | |
| Price To Earnings Diluted Ratio | -5.267 | -8.988 | 118.462 | -15.876 | -13.391 | |
| Price To Earnings Diluted Growth Ratio | -0.159 | 0.007 | -1.045 | 1.014 | 0.000 | |
| Price To Book Ratio | 1.213 | 1.912 | -5.697 | 9.855 | 6.284 | |
| Price To Sales Ratio | 0.000 | 0.000 | 7.740 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -5.700 | -11.354 | 20.439 | -19.122 | -14.641 | |
| Price To Operating Cash Flow Ratio | -5.724 | -11.532 | 20.002 | -19.234 | -14.734 | |
| Debt To Assets Ratio | 0.030 | 0.029 | 1.482 | 0.116 | 0.070 | |
| Debt To Equity Ratio | 0.032 | 0.032 | -2.844 | 0.149 | 0.080 | |
| Debt To Capital Ratio | 0.031 | 0.031 | 1.542 | 0.130 | 0.074 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 1.545 | 0.000 | 0.056 | |
| Financial Leverage Ratio | 1.060 | 1.075 | -1.919 | 1.289 | 1.145 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.613 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -5.677 | -3.293 | 3.528 | -2.665 | -7.149 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.387 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.004 | 1.016 | 0.979 | 1.006 | 1.006 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 111.168 | -5.428 | -17.912 | |
| Interest Coverage Ratio | 0.000 | 0.000 | -77.293 | -58.557 | -86.286 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -5.097 | -21.013 | |
| Operating Cash Flow Coverage Ratio | -6.704 | -5.248 | 0.100 | -3.440 | -5.351 | |
| Capital Expenditure Coverage Ratio | -239.446 | -63.901 | 46.737 | -170.517 | -156.345 | |
| Dividend Paid And Capex Coverage Ratio | -239.446 | -63.901 | 46.737 | -170.517 | -156.345 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.680 | -8.645 | 23.955 | -16.455 | -13.668 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-20.0% |
| Ebit Margin | 0.0% | 0.0% | ▼-9.3% |
| Ebitda Margin | 0.0% | 0.0% | ▼-9.4% |
| Operating Profit Margin | 0.0% | 0.0% | ▲6.4% |
| Pretax Profit Margin | 0.0% | 0.0% | ▼-9.3% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▼-9.1% |
| Net Profit Margin | 0.0% | 0.0% | ▼-9.1% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▼-9.1% |
| Current Ratio | 27.496 | ▲6.803 | ▲8.120 |
| Quick Ratio | 27.496 | ▲6.803 | ▲8.120 |
| Solvency Ratio | -3.811 | ▼-0.970 | ▼-1.440 |
| Cash Ratio | 7.759 | ▲5.559 | ▲4.801 |
| Price To Earnings Ratio | -5.267 | ▲3.720 | ▼-20.255 |
| Price To Earnings Growth Ratio | -0.159 | ▼-0.166 | ▼-0.122 |
| Forward Price To Earnings Growth Ratio | -0.159 | ▼-0.166 | ▼-0.122 |
| Price To Earnings Diluted Ratio | -5.267 | ▲3.720 | ▼-20.255 |
| Price To Earnings Diluted Growth Ratio | -0.159 | ▼-0.166 | ▼-0.122 |
| Price To Book Ratio | 1.213 | ▼-0.699 | ▼-1.500 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-1.548 |
| Price To Free Cash Flow Ratio | -5.700 | ▲5.654 | ▲0.375 |
| Price To Operating Cash Flow Ratio | -5.724 | ▲5.808 | ▲0.520 |
| Debt To Assets Ratio | 0.030 | ▲0.000 | ▼-0.315 |
| Debt To Equity Ratio | 0.032 | 0.000 | ▲0.542 |
| Debt To Capital Ratio | 0.031 | 0.000 | ▼-0.331 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.320 |
| Financial Leverage Ratio | 1.060 | ▼-0.015 | ▲0.530 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.123 |
| Operating Cash Flow Ratio | -5.676 | ▼-2.384 | ▼-2.625 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▼-0.077 |
| Free Cash Flow Operating Cash Flow Ratio | 1.004 | ▼-0.011 | ▲0.002 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▼-17.566 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲44.427 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲5.222 |
| Operating Cash Flow Coverage Ratio | -6.705 | ▼-1.457 | ▼-2.576 |
| Capital Expenditure Coverage Ratio | -239.446 | ▼-175.545 | ▼-122.751 |
| Dividend Paid And Capex Coverage Ratio | -239.446 | ▼-175.545 | ▼-122.751 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.680 | ▲4.965 | ▲0.019 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $316.6M | $378.8M | $387.0M | $387.0M | $387.0M | |
| Enterprise value | $249.3M | $363.1M | $564.7M | $387.3M | $387.3M | |
| EV / Sales | 0.00x | 0.00x | 11.29x | 0.00x | 0.00x | |
| EV / Op. cash flow | -4.51x | -11.05x | 29.18x | -19.25x | -14.74x | |
| EV / Free cash flow | -4.49x | -10.88x | 29.82x | -19.14x | -14.65x | |
| EV / EBITDA | -3.68x | -8.64x | 23.95x | -16.45x | -13.67x | |
| Net debt / EBITDA | 0.99x | 0.37x | 7.54x | -0.01x | -0.01x | |
| Current ratio | 27.50x | 20.69x | 23.29x | 6.41x | 18.99x | |
| Income quality | 0.92x | 0.78x | 0.85x | 0.83x | 0.91x | |
| Graham net-net | $9 | $7 | -$3 | $1 | $2 | |
| Tax burden | 100.0% | 100.0% | 98.1% | 100.0% | 100.0% | |
| Interest burden | 88.1% | 100.0% | 99.1% | 101.6% | 101.2% | |
| Working capital | $258.2M | $196.4M | $122.2M | $40.8M | $66.1M | |
| Invested capital | $266.6M | $202.9M | $123.6M | $43.0M | $66.7M | |
| Return on assets | -21.7% | -19.9% | 17.4% | -47.9% | -41.1% | |
| Operating ROA | -27.8% | -29.7% | -17.8% | -37.5% | 0.0% | |
| Return on tangible assets | -21.7% | -19.9% | 17.4% | -47.9% | -41.1% | |
| Return on equity | -23.0% | -21.3% | -33.4% | -61.8% | -47.1% | |
| Return on invested capital | -25.3% | -24.9% | -12.6% | -47.2% | -42.1% | |
| Return on capital employed | -25.5% | -25.1% | -12.9% | -52.7% | -42.9% | |
| Earnings yield | -18.9% | -11.2% | 5.9% | -6.3% | -7.5% | |
| Free cash flow yield | -17.5% | -8.8% | 4.9% | -5.2% | -6.8% | |
| Capex / Op. cash flow | -0.4% | -1.6% | 2.1% | -0.6% | -0.6% | |
| Capex / Depreciation | 71.5% | 199.2% | 212.3% | 35.9% | 51.7% | |
| Capex / Sales | 0.0% | 0.0% | 0.8% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 12.6% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 55.2% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 4.4% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 2562d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | -2562d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-25 Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of.
- 2026-07-30 Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results and affirmed its key clinical development milestones. “We continue to expand our footprint for PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients.
- 2026-07-09 Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice Does Contineum Therapeutics, Inc. (CTNM) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-06-30 Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the t
- 2026-06-30 Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the Journal of Medicinal Chemistry. The article, “Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatidic Acid R.